"BiolineRX has said in the past that it wants to conduct as many tests as possible for BL1020 in the early stages, in order to rule out as many poor candidates as possible and to improve recruitment of the best candidates for advanced and costly trials." That is what Dew would call the anti Zebra law approach!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.